MCID: PLS011
MIFTS: 60

Plasmacytoma

Categories: Rare diseases, Cancer diseases, Neuronal diseases, Blood diseases, Immune diseases

Aliases & Classifications for Plasmacytoma

MalaCards integrated aliases for Plasmacytoma:

Name: Plasmacytoma 12 53 59 55 44 15 73
Solitary Plasmacytoma 12 53 59
Solitary Osseous Plasmacytoma 73
Plasmacytoma - Category 73
Myeloma - Solitary 12
Myeloma, Solitary 12
Solitary Myeloma 12

Characteristics:

Orphanet epidemiological data:

59
plasmacytoma
Inheritance: Not applicable; Age of onset: Adult; Age of death: elderly;

Classifications:



External Ids:

Disease Ontology 12 DOID:3721
ICD10 33 C90.3 C90.30
MeSH 44 D010954
NCIt 50 C6932 C9349
Orphanet 59 ORPHA86855
MESH via Orphanet 45 D010954
UMLS via Orphanet 74 C0032131
ICD10 via Orphanet 34 C90.2 C90.3

Summaries for Plasmacytoma

MalaCards based summary : Plasmacytoma, also known as solitary plasmacytoma, is related to solitary osseous plasmacytoma and extramedullary plasmacytoma, and has symptoms including bone pain An important gene associated with Plasmacytoma is PVT1 (Pvt1 Oncogene
PVT1 is frequently involved in the translocations occurring in variant Burkitt's lymphomas and murine plasmacytomas.
Dysfunction Pattern: Mutation), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Reduced mammosphere formation and cellular

Wikipedia : 76 Plasmacytoma is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within... more...

Related Diseases for Plasmacytoma

Diseases related to Plasmacytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 246)
# Related Disease Score Top Affiliating Genes
1 solitary osseous plasmacytoma 33.1 B2M CD38
2 extramedullary plasmacytoma 33.0 B2M IGKC IL2 IL6
3 cervicitis 30.4 CD79A IL2
4 tonsillitis 30.3 CD79A IL2 IL6
5 intussusception 30.0 CD79A IL6
6 castleman disease 30.0 IL6 IL6R
7 b-cell lymphomas 29.9 IRF4 MYC PVT1
8 plasma cell neoplasm 29.4 B2M CD38 CD79A IL6 MYC PTPRC
9 plasmablastic lymphoma 29.1 CD38 MYC PTPRC
10 lymphoma, mucosa-associated lymphoid type 29.0 CD79A IGKC IRF4
11 amyloid tumor 28.9 B2M CD79A
12 combined immunodeficiency, x-linked 28.1 CD38 CD79A IL2 PTPRC
13 myeloma, multiple 27.4 B2M CD38 CD79A IL2 IL6 IL6R
14 extramedullary soft tissue plasmacytoma 12.1
15 anaplastic plasmacytoma 12.1
16 primary plasmacytoma of the bone 12.0
17 solitary plasmacytoma of chest wall 11.9
18 papillary conjunctivitis 10.7 IL11 IL6
19 streptococcal toxic-shock syndrome 10.6 IL2 IL6
20 uremic pruritus 10.6 IL2 IL6
21 ovarian lymphoma 10.6 MYC PTPRC
22 polyclonal hypergammaglobulinemia 10.6 CD79A IL6
23 sclerosing keratitis 10.6 B2M CD79A
24 orthostatic proteinuria 10.5 B2M CD79A
25 capillary leak syndrome 10.5 IL2 IL6
26 farmer's lung 10.5 CD79A IL2
27 diffuse glomerulonephritis 10.5 B2M CD79A
28 danubian endemic familial nephropathy 10.4 B2M CD79A
29 burning mouth syndrome 10.4 IL2 IL6
30 primary cutaneous anaplastic large cell lymphoma 10.4 IRF4 PTPRC
31 trichomoniasis 10.4 CD79A IL2
32 meningoencephalitis 10.3 B2M CD79A IL6
33 osteosclerotic myeloma 10.3 CD79A IL6
34 clonorchiasis 10.3 CD79A IL2
35 joint disorders 10.3 IL11 IL6 IL6R
36 colon lymphoma 10.3 IRF4 PTPRC
37 urinary system disease 10.3 B2M CD79A IL6
38 small intestine lymphoma 10.3 B2M CD79A PTPRC
39 kaposi sarcoma 10.3 IL6 IL6ST MYC
40 photokeratitis 10.3 IL6 PTPRC
41 microscopic colitis 10.3 CD79A IL2 IL6
42 human herpesvirus 8 10.2 IL6 IL6R IL6ST
43 commensal bacterial infectious disease 10.2 CD79A IL2 IL6
44 thyroiditis 10.2
45 exanthem 10.2 CD79A IL2 IL6
46 preterm premature rupture of the membranes 10.2 IL6 IL6R IL6ST
47 lymphoma 10.2
48 parasitic protozoa infectious disease 10.2 CD79A IL2 IL6
49 primary bacterial infectious disease 10.2 CD79A IL2 IL6
50 primary effusion lymphoma 10.2 IL6 IRF4 MYC

Graphical network of the top 20 diseases related to Plasmacytoma:



Diseases related to Plasmacytoma

Symptoms & Phenotypes for Plasmacytoma

UMLS symptoms related to Plasmacytoma:


bone pain

GenomeRNAi Phenotypes related to Plasmacytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.1 IL6R IL6ST MYC PTPRC CD79A EBF1

MGI Mouse Phenotypes related to Plasmacytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.17 B2M IL6 CD38 IL6R CD79A EBF1
2 hematopoietic system MP:0005397 10.06 B2M IL6 CD38 IL6R CD79A EBF1
3 endocrine/exocrine gland MP:0005379 9.97 B2M IL6 CD38 IL6R IL6ST IL2
4 homeostasis/metabolism MP:0005376 9.96 IL2 B2M IL6 CD38 CD79A IL6R
5 adipose tissue MP:0005375 9.93 IL6 IL6R EBF1 IL6ST IRF4 MYC
6 immune system MP:0005387 9.9 B2M IL6 CD38 IL6R CD79A EBF1
7 digestive/alimentary MP:0005381 9.88 IL2 B2M IL6 MYC PTPRC IL6ST
8 liver/biliary system MP:0005370 9.61 IL6 IL6R CD79A EBF1 IL6ST IL2
9 neoplasm MP:0002006 9.28 IL6 IL6R CD79A IL6ST IL2 B2M

Drugs & Therapeutics for Plasmacytoma

Drugs for Plasmacytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 438)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Bortezomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
4
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
5
Lenalidomide Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 191732-72-6 216326
6
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 52-24-4 5453
7 Ixazomib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1072833-77-2
8
Glycine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 56-40-6 750
9 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Antilymphocyte Serum Phase 4,Phase 2,Phase 1,Not Applicable
11 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
24 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Proteasome Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
35
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
36
Carmustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 154-93-8 2578
37
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 83-43-2 6741
38
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-24-8 5755
39
Prednisone Approved, Vet_approved Phase 3,Phase 1,Phase 2 53-03-2 5865
40
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
41
Idarubicin Approved Phase 3 58957-92-9 42890
42
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
43
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
44
Iron Approved Phase 3,Phase 2,Phase 1 7439-89-6 23925
45
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
46
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 128794-94-5 5281078
47
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
48
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
49
Zoledronic acid Approved Phase 3,Phase 2,Phase 1 118072-93-8 68740
50
Pamidronate Approved Phase 3,Phase 2,Phase 1 40391-99-9 4674

Interventional clinical trials:

(show top 50) (show all 550)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
3 CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
4 High-Dose Melphalan and a Second Stem Cell Transplant or Low-Dose Cyclophosphamide in Treating Patients With Relapsed Multiple Myeloma After Chemotherapy Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
5 Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
6 Combination Chemotherapy and Interferon Alfa With or Without Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloma Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
7 Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
8 Combination Chemotherapy With or Without Cyclophosphamide and Prednisone in Treating Older Patients With Multiple Myeloma Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
9 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
10 Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
11 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
12 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
13 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
14 Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma Completed NCT00432458 Phase 3 Thalidomide;zoledronic acid
15 Melphalan With or Without Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00008229 Phase 3 melphalan
16 Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00002878 Phase 3 dexamethasone;doxorubicin hydrochloride;valspodar;vincristine sulfate
17 Thalidomide and Prednisone After Autologous Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00049673 Phase 3 prednisone;thalidomide
18 Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma Completed NCT00033332 Phase 3 dexamethasone;pamidronate disodium;thalidomide;zoledronic acid
19 Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00017602 Phase 3 dexamethasone
20 Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma Completed NCT00006232 Phase 3 dexamethasone;doxorubicin hydrochloride;idarubicin;vincristine sulfate
21 Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma Completed NCT00004165 Phase 3 melphalan
22 Combination Chemotherapy in Treating Patients With Multiple Myeloma Completed NCT00002678 Phase 3 dexamethasone;melphalan;prednisone
23 Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis Completed NCT00477971 Phase 3 dexamethasone;melphalan
24 S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma Completed NCT00064038 Phase 3 dexamethasone;lenalidomide
25 Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure Completed NCT00416897 Phase 3 chemotherapy;dexamethasone
26 Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma Completed NCT00813150 Phase 3 Dexamethasone;Bortezomib;Cyclophosphamide
27 Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma Completed NCT01324947 Phase 3 pomalidomide
28 Velcade (Bortezomib) Consolidation After Transplant Completed NCT01539083 Phase 3 Thalidomide;Bortezomib;Cyclophosphamide;Dexamethasone;Prednisolone
29 A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed NCT00424047 Phase 3 CC-5013 plus dexamethasone;Dexamethasone plus Placebo
30 A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multi Completed NCT01311687 Phase 3 pomalidomide;dexamethasone
31 Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone Completed NCT00507416 Phase 3 Bortezomib;Dexamethasone;Melphalan;Prednisone;Thalidomide
32 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. Completed NCT00405756 Phase 3 Lenalidomide: Double-blind Induction;Melphalan;Prednisone;Aspirin;Placebo;Lenalidomide: Double-blind Maintenance;Lenalidomide: Open-label
33 UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Completed NCT01621672 Phase 3 Revlimid
34 A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma Completed NCT00478777 Phase 3 Lenalidomide;dexamethasone
35 Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma Completed NCT00103506 Phase 3 Bortezomib (VELCADE);Bortezomib (VELCADE);Doxorubicin hydrochloride (DOXIL/CAELYX)
36 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
37 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
38 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
39 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
40 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
41 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
42 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
43 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
44 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
45 Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma Completed NCT01080391 Phase 3 Dexamethasone;Lenalidomide;Carfilzomib
46 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
47 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed NCT00075829 Phase 3 Thalidomide;Dexamethasone
48 Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
49 Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma Completed NCT00002556 Phase 3 vincristine sulfate;carmustine;melphalan;cyclophosphamide;prednisone
50 A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma Completed NCT00928486 Phase 3 Lenalidomide;Dexamethasone

Search NIH Clinical Center for Plasmacytoma

Cochrane evidence based reviews: plasmacytoma

Genetic Tests for Plasmacytoma

Anatomical Context for Plasmacytoma

MalaCards organs/tissues related to Plasmacytoma:

41
Bone, Bone Marrow, T Cells, Kidney, B Cells, Thyroid, Myeloid

Publications for Plasmacytoma

Articles related to Plasmacytoma:

(show top 50) (show all 1113)
# Title Authors Year
1
A rare case of a minimally secretory plasma cell leukemia with a hemorrhagic gastric plasmacytoma. ( 29892544 )
2018
2
Multiple myeloma causing interstitial pulmonary infiltrates and soft-tissue plasmacytoma. ( 29977785 )
2018
3
Extramedullary plasmacytoma. ( 29496243 )
2018
4
Treatment of relapsed multiple myeloma complicated by cardiac extramedullary plasmacytoma with D-PACE chemotherapy. ( 29523615 )
2018
5
Atypical Presentation of Extramedullary Plasmacytoma. ( 29559881 )
2018
6
Tonsillar Plasmacytoma: clues on magnetic resonance imaging. ( 29914385 )
2018
7
Extramedullary plasmacytoma of the trachea: A case report and review of the literature. ( 29504982 )
2018
8
Anaplastic plasmacytoma: a rare tumor presenting as a pathological fracture in a younger adult. ( 29388036 )
2018
9
Plasmacytoma of the Skull-base: A Rare Tumor. ( 29552435 )
2018
10
Gastrointestinal manifestations of extramedullary plasmacytoma: a narrative review and illustrative case reports. ( 29692194 )
2018
11
Extramedullary plasmacytoma of the testis: A case report. ( 29204364 )
2018
12
Collet-Sicard Syndrome Attributable to Extramedullary Plasmacytoma of the Jugular Foramen. ( 29191538 )
2018
13
Primary orbital plasmacytoma: An unusual presentation in an adolescent. ( 29567915 )
2018
14
Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and Daratumumab. ( 29636948 )
2018
15
Skull base plasmacytoma: A unique case of POEMS syndrome with a plasmacytoma causing craniocervical instability. ( 29100675 )
2018
16
Multicentric plasmacytoma in a harbor porpoise Phocoena phocoena off the coast of Whidbey Island, Washington State, USA. ( 29516861 )
2018
17
Pattern of care and impact of prognostic factors on the outcome of head and neck extramedullary plasmacytoma: a systematic review and individual patient data analysis of 315 cases. ( 29224044 )
2018
18
CD3<sup>+</sup> CD56<sup>+</sup> EBER1<sup>+</sup> atypical extraosseous plasmacytoma of the nasal cavity. ( 29572766 )
2018
19
Plasmacytoma. ( 29779914 )
2018
20
Testicular plasmacytoma: unique location or circumstantial presentation? ( 29316841 )
2018
21
Late Relapse of Multiple Myeloma with Testicular Plasmacytoma after Autologous Hematopoietic Stem Cell Transplantation: A Case Report and Review of the Literature. ( 29531008 )
2018
22
Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. ( 29338789 )
2018
23
Primary extramedullary plasmacytoma of the sigmoid colon with perforation: a case report. ( 29619633 )
2018
24
Testicular plasmacytoma misdiagnosed as orchitis. ( 29866662 )
2018
25
Neurosurgical rare disease: solitary plasmacytoma of the skull - case report and literature review. ( 29940651 )
2018
26
Extramedullary plasmacytoma: rare neoplasm of parotid gland. ( 29301803 )
2018
27
Solitary plasmacytoma of the jaws: therapeutical considerations and prognosis based on a case reports systematic survey. ( 29941386 )
2018
28
Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group. ( 29976492 )
2018
29
Dural Plasmacytoma with Meningeal Myelomatosis in a Patient with Multiple Myeloma. ( 29651350 )
2018
30
Corrigendum to &amp;quot;Collision Tumor With Renal Cell Carcinoma and Plasmacytoma: Further Evidence of a Renal Cell and Plasma Cell Neoplasm Relationship?&amp;quot; [Urology Case Reports 6 (2017) 50-52]. ( 29541578 )
2017
31
Epibulbar Plasmacytoma Masquerading as Subconjunctival Hemorrhage in a Patient With Multiple Myeloma. ( 28060076 )
2017
32
Plasmacytoma of the clivus. ( 28761547 )
2017
33
Bilateral plasmacytoma of the breast. ( 28805290 )
2017
34
Primary extraosseous plasmacytoma of the parotid gland: A case report and literature review. ( 29181165 )
2017
35
C2 Solitary Bone Plasmacytoma Curettage and Vertebral Augmentation in an 83-Year-Old Female: Case Report and Review of Surgical Treatment Approaches in the Spine. ( 29391960 )
2017
36
Uterine Extramedullary Plasmacytoma as a Primary Manifestation of Multiple Myeloma. ( 28834996 )
2017
37
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue with plasma cell differentiation: Periodic acid-schiff reaction-positive Dutcher body is a diagnostic clue to distinguish it from plasmacytoma. ( 28233949 )
2017
38
Sellar plasmacytoma presenting with symptoms of anterior pituitary dysfunction. ( 29204279 )
2017
39
LncRNA plasmacytoma variant translocation 1 is an oncogene in bladder urothelial carcinoma. ( 28969069 )
2017
40
Extramedullary Plasmacytoma Arising From the Anterior Mediastinum. ( 28431708 )
2017
41
Desmin-positive anaplastic plasmacytoma involving the nasopharynx. ( 28168725 )
2017
42
Progression of cutaneous plasmacytoma to plasma cell leukemia in a dog. ( 28186653 )
2017
43
Survival of patients with lymphoplasmacytic lymphoma and solitary plasmacytoma in Germany and the United States of America in the early 21(st) century. ( 28280077 )
2017
44
Clinical findings in 25 patients with sinonasal or nasopharyngeal extramedullary plasmacytoma in a four-decade single-centre series. ( 28537101 )
2017
45
An Extremely Rare Manifestation of Multiple Myeloma: An Immunoglobulin D Secreting Testicular Plasmacytoma. ( 28845377 )
2017
46
A rare case of Epstein-Barr virus-related plasmacytoma involving maxillary sinus mucosa. ( 28878909 )
2017
47
Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis in 55 patients. ( 29142463 )
2017
48
Extramedullary plasmacytoma occuring in ileocecum: A case report and literature review. ( 29390503 )
2017
49
Extramedullary plasmacytoma of the testicle. ( 29205163 )
2017
50
Rare Presentation of Primary Extramedullary Plasmacytoma as Lip Lesion. ( 28409043 )
2017

Variations for Plasmacytoma

Expression for Plasmacytoma

Search GEO for disease gene expression data for Plasmacytoma.

Pathways for Plasmacytoma

Pathways related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.9 B2M CD79A IL11 IL2 IL6 IL6R
2
Show member pathways
13.14 B2M IL11 IL2 IL6 IL6R IL6ST
3 12.72 IL2 IL6 IL6R IL6ST MYC
4
Show member pathways
12.32 IL2 IL6 IRF4 PTPRC
5
Show member pathways
12.31 IL2 IL6 IL6R IL6ST IRF4
6
Show member pathways
12.27 CD79A IRF4 MYC PTPRC
7 12.21 B2M CD38 CD79A IL2 IL6ST IRF4
8
Show member pathways
12.1 IL11 IL2 IL6 IL6R IL6ST IRF4
9
Show member pathways
12.04 IL11 IL2 IL6 IL6R IL6ST
10
Show member pathways
11.98 IL6 IL6R IL6ST
11
Show member pathways
11.97 IL11 IL2 IL6 IL6R MYC
12 11.94 IL11 IL6 MYC
13 11.93 EBF1 IL6 IL6ST
14 11.88 IL2 IL6 MYC
15 11.87 IL6 IL6R IRF4 MYC
16 11.82 IL6 IL6R IL6ST
17 11.76 CD38 IL11 IL6 IL6R
18
Show member pathways
11.73 IL6 IL6R IL6ST IRF4
19 11.7 IL2 IRF4 PTPRC
20 11.66 IL2 IL6 IL6R IL6ST PTPRC
21
Show member pathways
11.64 IL6 IL6R IL6ST MYC
22 11.52 CD38 IL2 IL6 IRF4 PTPRC
23 11.48 CD38 IL6R PTPRC
24 11.46 IL6 IL6R MYC
25 11.42 IL11 IL6 IL6R
26
Show member pathways
11.35 IL6 IL6R IL6ST
27 11.23 IL6 IL6R IL6ST
28 11.18 IL11 IL2 IL6
29 11.16 CD38 CD79A IL11 IL2 IL6 PTPRC

GO Terms for Plasmacytoma

Cellular components related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 B2M CNTN3 IGKC IL11 IL2 IL6
2 external side of plasma membrane GO:0009897 9.35 B2M CD79A IGKC IL6ST PTPRC
3 ciliary neurotrophic factor receptor complex GO:0070110 9.16 IL6R IL6ST
4 interleukin-6 receptor complex GO:0005896 8.8 IL6 IL6R IL6ST

Biological processes related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 22)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.93 CD38 IL2 IL6 IL6ST MYC
2 positive regulation of cell proliferation GO:0008284 9.85 IL11 IL2 IL6 IL6R IL6ST MYC
3 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.72 IL11 IL6 IL6R
4 response to cytokine GO:0034097 9.7 CD38 IL6R IL6ST
5 positive regulation of osteoblast differentiation GO:0045669 9.67 IL6 IL6R IL6ST
6 positive regulation of smooth muscle cell proliferation GO:0048661 9.65 IL6 IL6R MYC
7 B cell receptor signaling pathway GO:0050853 9.62 CD38 CD79A IGKC PTPRC
8 endocrine pancreas development GO:0031018 9.61 IL6 IL6R
9 positive regulation of B cell proliferation GO:0030890 9.61 CD38 IL2 PTPRC
10 positive regulation of leukocyte chemotaxis GO:0002690 9.6 IL6 IL6R
11 positive regulation of chemokine production GO:0032722 9.59 IL6 IL6R
12 negative regulation of bone resorption GO:0045779 9.58 CD38 IL6
13 positive regulation of immunoglobulin secretion GO:0051024 9.57 IL2 IL6
14 positive regulation of acute inflammatory response GO:0002675 9.56 IL6 IL6ST
15 T-helper 17 cell lineage commitment GO:0072540 9.51 IL6 IRF4
16 ciliary neurotrophic factor-mediated signaling pathway GO:0070120 9.46 IL6R IL6ST
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.46 IL2 IL6 IL6R IL6ST
18 interleukin-6-mediated signaling pathway GO:0070102 9.43 IL6 IL6R IL6ST
19 hepatic immune response GO:0002384 9.4 IL6 IL6R
20 positive regulation of T cell proliferation GO:0042102 9.26 IL2 IL6 IL6ST PTPRC
21 cytokine-mediated signaling pathway GO:0019221 9.17 IL11 IL2 IL6 IL6R IL6ST IRF4
22 positive regulation of transcription by RNA polymerase II GO:0045944 10.05 EBF1 IL11 IL2 IL6 IRF4 MYC

Molecular functions related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ciliary neurotrophic factor receptor activity GO:0004897 9.26 IL6R IL6ST
2 interleukin-6 receptor activity GO:0004915 9.16 IL6R IL6ST
3 interleukin-6 binding GO:0019981 8.96 IL6R IL6ST
4 interleukin-6 receptor binding GO:0005138 8.8 IL6 IL6R IL6ST

Sources for Plasmacytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....